Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced or Metastatic Pancreatic Cancer With FGFR Alterations
NCT06906562Phase 2
Key facts
- Status
- Recruiting
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Countries
- 1
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Drugs
- pemigatinib
- Conditions
- pancreatic cancer (PC)
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in pancreatic cancer (PC). Primary endpoint: Overall Response Rate at 24 months. Started Aug 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Pemigatinib Treatment
Pemigatinib PO QD on days 1-14 of each 21-day cycle
03
Who it enrols
Adult patients with advanced or metastatic pancreatic cancer with FGFR2 fusions/translocations or other FGFR alterations, who have progressed on at least one prior standard of care therapy, with adequate organ function and ECOG PS 0-1.
04
Endpoints
Primary
Overall Response Rate
Secondary
Progression Free Survival
Disease Control Rate
Overall Survival
Adverse Events
Best Overall Response
Beyond the preview
Go deeper on NCT06906562.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06906562.